Department of Health and Human Services$1.1M obligationsEnds Dec 18, 2021
Federal contract award
75N94018F00005
CCTN FEMALE SITES
Award details
Obligations, current value and potential value describe different measures; they are never added together.
| Field | Reported value |
|---|---|
| Agency | Department of Health and Human Services |
| Office | NATIONAL INSTITUTES OF HEALTH NICHD |
| NAICS | 541712 |
| PSC | AN12 — HEALTH R&D SERVICES; HEALTH CARE SERVICES; APPLIED RESEARCH |
| Parent award / vehicle | HHSN275201300003I |
| Set-aside | Not reported |
| Pricing type | COST NO FEE |
| Obligations | $506.7K |
| Current contract value | $506.7K |
| Potential contract value / ceiling | $506.7K |
| Start date | Sep 24, 2018 |
| Current end date | Jul 14, 2026 |
| Potential end date | Jul 14, 2026 |
| Latest award activity | May 27, 2025 |
| Source loaded | Sep 26, 2026 |
Funding and modification history
Showing the latest 5 of 5 loaded transactions. Negative values are deobligations.
| Date | Modification | Obligation change | Description |
|---|---|---|---|
| May 27, 2025 | P00004 | $0 | CONTRACEPTIVE CLINICAL TRIALS NETWORK - FEMALE SITES POP 09/28/18 - 07/14/26; NICHD; R&D TO EVALUATE IN OBESE AND NON-OBESE WOMEN THE PHARMACOKINETICS (PK) AND THE PHARMACODYNAMIC (PD) EFFECTS, CYCLE CONTROL, AND SAFETY OF LEVONORGESTREL BUTANO |
| Jan 12, 2024 | P00003 | $111.6K | CONTRACEPTIVE CLINICAL TRIALS NETWORK - FEMALE SITES POP 09/28/18 - 07/14/25 TO EVALUATE IN OBESE AND NON-OBESE WOMEN THE PHARMACOKINETICS (PK) AND THE PHARMACODYNAMIC (PD) EFFECTS, CYCLE CONTROL, AND SAFETY OF LEVONORGESTREL BUTANOATE (LB) FORMULA |
| Sep 25, 2023 | P00002 | $65.9K | CONTRACEPTIVE CLINICAL TRIALS NETWORK - FEMALE SITES POP 09/28/18 - 01/15/24 TO EVALUATE IN OBESE AND NON-OBESE WOMEN THE PHARMACOKINETICS (PK) AND THE PHARMACODYNAMIC (PD) EFFECTS, CYCLE CONTROL, AND SAFETY OF LEVONORGESTREL BUTANOATE (LB) FORMULA |
| Sep 27, 2021 | P00001 | $115.2K | CONTRACEPTIVE CLINICAL TRIALS NETWORK - FEMALE SITES POP 09/28/18 - 09/27/23 TO EVALUATE IN OBESE AND NON-OBESE WOMEN THE PHARMACOKINETICS (PK) AND THE PHARMACODYNAMIC (PD) EFFECTS, CYCLE CONTROL, AND SAFETY OF LEVONORGESTREL BUTANOATE (LB) FORMULATE |
| Sep 26, 2018 | 0 | $214.0K | CCTN FEMALE SITES |
Research next steps
- Confirm the ordering vehicle and your eligibility or a qualified teaming route.
- Review the award scope and buyer evidence before making a bid/no-bid decision.